Ligand id: 7541

Name: ixekizumab

1. Allan A, Chow C-K , Liu L, Lu J, Tetreault JW. (2010)
Interleukin specific monoclonal antibody for use in treatment and prevention of autoimmune, cell proliferative, inflammatory and developmental disorders.
Patent number: US7838638. Assignee: Eli Lilly And Company. Priority date: 13/12/2005. Publication date: 23/11/2010.
2. Blauvelt A, Papp KA, Griffiths CE, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. (2017)
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Am J Clin Dermatol18 (2): 273-280. [PMID:28074446]
3. Burkett PR, Kuchroo VK. (2016)
IL-17 Blockade in Psoriasis.
Cell167 (7): 1669. [PMID:27984714]
4. Dong J, Goldenberg G. (2017)
New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Cutis99 (2): 123-127. [PMID:28319618]
5. Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, Lee K, Bhutani T, Koo J. (2016)
Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Dermatol Ther (Heidelb)6 (1): 25-37. [PMID:26910853]
6. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY et al.. (2014)
Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-naïve or TNF-IR patients with rheumatoid arthritis.
Arthritis Rheumatol,  [Epub ahead of print]. [PMID:24623718]
7. Girolomoni G, Mrowietz U, Paul C. (2012)
Psoriasis: rationale for targeting interleukin-17.
Br. J. Dermatol.167 (4): 717-24. [PMID:22716185]
8. Gordon KB, Blauvelt AB, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK et al.. (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
New England Journal of Medicine,  Online first.
9. Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T et al.. (2012)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
J. Allergy Clin. Immunol.130 (1): 145-54.e9. [PMID:22677045]
10. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL et al.. (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Lancet,  [Epub ahead of print]. [PMID:28551073]